Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

FORM by GBY vs Invigor Medical

Two GLP-1 desks, one scoreboard. We put FORM by GBY and Invigor Medical head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 199 · Grade C

FORM by GBY

Visit FORM by GBY Full brief →
vs
Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 67 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make FORM by GBY a bad call — it's best for readers who want the widest single-account menu and are willing to complete intake to learn what the branded and adjacent-care lines actually cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
55
87
Supply Reliability
78
88
Transparency
42
84
Access Breadth
82
82
Clinical Oversight
60
88
Track Record
68
90
FORM by GBYBrief Score 67 · 88Invigor Medical

Price, coverage & the tracker

FORM by GBYInvigor Medical
Brief Score67/100 (C)88/100 (B+)
Semaglutide$299/mo (compounded, no dose tiers published)$199/mo
TirzepatideNot disclosed (Zepbound membership offered, drug cost not published)$339/mo
Coverage48 states + DC (excludes Alaska, Mississippi)Not disclosed
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

FORM by GBY: First reading — one real price (compounded sema $299); everything else, including the advertised Wegovy "$95," is a membership fee or undisclosed.

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.